NO20072755L - Fremgangsmate for fremstilling av 4-(6-klor-2-metylendioksyanilino)-7-2-(4-metylpiperazin-1-yl)etoksy]-5-tetrahydropyran-4-yloksykinazolin, deres mellomprodukter og krystallinske salter derav - Google Patents
Fremgangsmate for fremstilling av 4-(6-klor-2-metylendioksyanilino)-7-2-(4-metylpiperazin-1-yl)etoksy]-5-tetrahydropyran-4-yloksykinazolin, deres mellomprodukter og krystallinske salter deravInfo
- Publication number
- NO20072755L NO20072755L NO20072755A NO20072755A NO20072755L NO 20072755 L NO20072755 L NO 20072755L NO 20072755 A NO20072755 A NO 20072755A NO 20072755 A NO20072755 A NO 20072755A NO 20072755 L NO20072755 L NO 20072755L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- intermediates
- yloxyquinazoline
- methylenedioxyanilino
- methylpiperazin
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 title 1
- -1 6-Chloro-2-methylenedioxyanilino Chemical group 0.000 title 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 abstract 2
- 238000001311 chemical methods and process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229950009919 saracatinib Drugs 0.000 abstract 1
- 150000004684 trihydrates Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0427697.8A GB0427697D0 (en) | 2004-12-17 | 2004-12-17 | Chemical process |
| PCT/GB2005/004807 WO2006064217A2 (en) | 2004-12-17 | 2005-12-14 | PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072755L true NO20072755L (no) | 2007-07-02 |
Family
ID=34090249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072755A NO20072755L (no) | 2004-12-17 | 2007-05-30 | Fremgangsmate for fremstilling av 4-(6-klor-2-metylendioksyanilino)-7-2-(4-metylpiperazin-1-yl)etoksy]-5-tetrahydropyran-4-yloksykinazolin, deres mellomprodukter og krystallinske salter derav |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8304417B2 (https=) |
| EP (1) | EP1871769B1 (https=) |
| JP (2) | JP5161584B2 (https=) |
| KR (6) | KR20080094847A (https=) |
| CN (1) | CN101115744B (https=) |
| AU (2) | AU2005315458B2 (https=) |
| BR (1) | BRPI0519085A2 (https=) |
| CA (2) | CA2590735C (https=) |
| ES (1) | ES2622480T3 (https=) |
| GB (1) | GB0427697D0 (https=) |
| IL (1) | IL183525A0 (https=) |
| MX (1) | MX2007007210A (https=) |
| NO (1) | NO20072755L (https=) |
| NZ (1) | NZ555468A (https=) |
| WO (1) | WO2006064217A2 (https=) |
| ZA (1) | ZA200704532B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
| WO2009068906A2 (en) * | 2007-11-26 | 2009-06-04 | Astrazeneca Ab | Combinations comprising zd4054 and a src family kinase inhibitor 172 |
| CN103275072B (zh) * | 2013-05-22 | 2016-01-20 | 苏州明锐医药科技有限公司 | 塞卡替尼的制备方法 |
| US11241434B2 (en) | 2013-06-13 | 2022-02-08 | Yale Uninversity | Compositions and methods for improving cognition in a subject |
| US10660957B2 (en) * | 2013-06-13 | 2020-05-26 | Yale University | Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject |
| US10369152B2 (en) | 2015-02-13 | 2019-08-06 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue |
| PT3930715T (pt) | 2019-02-27 | 2024-08-02 | Astrazeneca Ab | Saracatinib para uso no tratamento de fibrose pulmonar idiopática |
| CN116332789A (zh) * | 2023-03-10 | 2023-06-27 | 上海康鹏科技股份有限公司 | 一种4-氨基-2-氟苯甲酰胺的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| CA2419301C (en) | 2000-08-21 | 2009-12-08 | Astrazeneca Ab | Quinazoline derivatives |
| DE60229046D1 (de) | 2001-04-19 | 2008-11-06 | Astrazeneca Ab | Chinazolin derivate |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| GB0226434D0 (en) | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| GB0307333D0 (en) | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
-
2004
- 2004-12-17 GB GBGB0427697.8A patent/GB0427697D0/en not_active Ceased
-
2005
- 2005-12-14 KR KR1020087023971A patent/KR20080094847A/ko not_active Withdrawn
- 2005-12-14 AU AU2005315458A patent/AU2005315458B2/en not_active Expired
- 2005-12-14 US US11/793,064 patent/US8304417B2/en active Active
- 2005-12-14 CA CA002590735A patent/CA2590735C/en not_active Expired - Lifetime
- 2005-12-14 KR KR1020087023973A patent/KR20080094849A/ko not_active Withdrawn
- 2005-12-14 CA CA002675642A patent/CA2675642A1/en not_active Abandoned
- 2005-12-14 ES ES05818127.2T patent/ES2622480T3/es not_active Expired - Lifetime
- 2005-12-14 KR KR1020077015972A patent/KR20070090004A/ko not_active Ceased
- 2005-12-14 JP JP2007546172A patent/JP5161584B2/ja not_active Expired - Lifetime
- 2005-12-14 WO PCT/GB2005/004807 patent/WO2006064217A2/en not_active Ceased
- 2005-12-14 KR KR1020117022793A patent/KR20110114727A/ko not_active Ceased
- 2005-12-14 KR KR1020087023969A patent/KR20080094846A/ko not_active Withdrawn
- 2005-12-14 EP EP05818127.2A patent/EP1871769B1/en not_active Expired - Lifetime
- 2005-12-14 MX MX2007007210A patent/MX2007007210A/es not_active Application Discontinuation
- 2005-12-14 BR BRPI0519085-1A patent/BRPI0519085A2/pt not_active IP Right Cessation
- 2005-12-14 CN CN2005800476248A patent/CN101115744B/zh not_active Expired - Lifetime
- 2005-12-14 NZ NZ555468A patent/NZ555468A/en not_active IP Right Cessation
- 2005-12-14 KR KR1020087023972A patent/KR20080094848A/ko not_active Withdrawn
-
2007
- 2007-05-29 IL IL183525A patent/IL183525A0/en unknown
- 2007-05-30 NO NO20072755A patent/NO20072755L/no not_active Application Discontinuation
- 2007-05-31 ZA ZA200704532A patent/ZA200704532B/en unknown
-
2008
- 2008-12-15 JP JP2008318186A patent/JP2009143920A/ja active Pending
-
2009
- 2009-02-18 AU AU2009200622A patent/AU2009200622A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200704532B (en) | 2008-07-30 |
| CN101115744A (zh) | 2008-01-30 |
| KR20080094847A (ko) | 2008-10-24 |
| US8304417B2 (en) | 2012-11-06 |
| EP1871769A2 (en) | 2008-01-02 |
| KR20080094846A (ko) | 2008-10-24 |
| KR20110114727A (ko) | 2011-10-19 |
| US20090099196A1 (en) | 2009-04-16 |
| CA2675642A1 (en) | 2006-06-22 |
| EP1871769B1 (en) | 2017-02-22 |
| JP5161584B2 (ja) | 2013-03-13 |
| KR20080094849A (ko) | 2008-10-24 |
| AU2005315458B2 (en) | 2009-03-12 |
| AU2005315458A1 (en) | 2006-06-22 |
| CA2590735C (en) | 2009-11-10 |
| BRPI0519085A2 (pt) | 2008-12-23 |
| NZ555468A (en) | 2010-12-24 |
| WO2006064217A3 (en) | 2006-12-21 |
| WO2006064217A2 (en) | 2006-06-22 |
| WO2006064217A8 (en) | 2007-07-05 |
| MX2007007210A (es) | 2007-11-07 |
| IL183525A0 (en) | 2007-09-20 |
| AU2009200622A1 (en) | 2009-03-12 |
| KR20070090004A (ko) | 2007-09-04 |
| JP2008524183A (ja) | 2008-07-10 |
| CA2590735A1 (en) | 2006-06-22 |
| CN101115744B (zh) | 2012-02-01 |
| JP2009143920A (ja) | 2009-07-02 |
| ES2622480T3 (es) | 2017-07-06 |
| KR20080094848A (ko) | 2008-10-24 |
| GB0427697D0 (en) | 2005-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072755L (no) | Fremgangsmate for fremstilling av 4-(6-klor-2-metylendioksyanilino)-7-2-(4-metylpiperazin-1-yl)etoksy]-5-tetrahydropyran-4-yloksykinazolin, deres mellomprodukter og krystallinske salter derav | |
| NO20083542L (no) | Nye kumarinderivater med antitumoraktivitet | |
| NO20063748L (no) | Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer | |
| NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
| NO20063468L (no) | Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister | |
| NO20071504L (no) | Pyrimidinderivanter. | |
| NO20063469L (no) | Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister | |
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| NO20055219L (no) | Nye forbindelser | |
| NO20051826L (no) | Heterosyklisk substituerte piperaziner for behandling av schizofreni | |
| NO20073572L (no) | Nye forbindelser | |
| NO20084363L (no) | 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister | |
| NO20075113L (no) | Proteinkinaseinhibitorer | |
| NO20075059L (no) | Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase | |
| NO20073730L (no) | Amidderivater | |
| NO20071245L (no) | Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer. | |
| NO20085212L (no) | Nye pyridinanaloger | |
| NO20076695L (no) | Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser | |
| NO20071745L (no) | Hydroklorid av 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| SG171681A1 (en) | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| NO20074303L (no) | 7-{4-[2-(2,6-diklor-4-metylfenoksy)etoksy]fenyl}-3,9-diazabisyklo-[3.3.1]non-6-en-6-karboksylsyresyklopropyl-(2,3-dimetylbenzyl)amid som renininhibitor til behandling av hypertensjon | |
| NO20076682L (no) | Nye pyridinanaloger | |
| NO20082054L (no) | Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |